No specialty spends more administrative effort per prescription than rheumatology.

The RealityThe packet is the bottleneck

⚠️

The Problem

The justification is buried in prose.

Prior agents, dates, reasons for discontinuation and disease activity all sit inside narrative notes. Every submission starts with someone reading and retyping.

🔧

The Solution

Capture the criteria as you go.

Record therapy history and activity scores as structured fields during the visit, then assemble the packet from the record instead of reconstructing it afterwards.

✅

The Resolution

Submitted the same week, tracked to a decision.

The packet is built in minutes, every submission has an owner and a status, and nothing sits waiting because nobody realized it was waiting.

Documentation requirements: assembling the packet once

Start with the observation that the same twelve or so data points are requested for most agents, with variations. Therapy history with dates. Reason each prior agent was stopped. A disease activity measure, ideally repeated. Screening results. Relevant comorbidities. Weight where dosing depends on it.

The retyping problem, stated plainly

If those twelve points are captured as structured fields during the visit, the documentation requirements for a submission are met by pulling a report. If they are captured in prose, every submission is a research exercise. The clinical content is identical either way. Only the retrievability differs, and retrievability is a configuration decision that was made once, probably at go-live, probably by default.

This is the single highest-return change available to a rheumatology practice, and it is unglamorous. a template that assembles the packet from fields the clinician already completes turns a thirty-minute reconstruction into a two-minute review. It also improves the note, because structured therapy history is easier to read than a paragraph.

Payer policy: the criteria you are actually being judged against

Most practices submit against what they believe the criteria are rather than against the published policy. The published policy is usually available, usually specific, and usually different in some small way from what everyone assumes.

Pull the current policy for the three or four agents you prescribe most, for the plans that cover most of your patients. Read what is actually required. Then compare it to what your submissions contain. In our engagements this exercise almost always finds at least one item that is being supplied unnecessarily and at least one that is routinely missing and causes avoidable back-and-forth.

Payer policy changes, so this is a periodic task rather than a one-off. Twice a year, on a calendar, assigned to a named person. It is an hour of work that prevents a category of denial that feels arbitrary and is not.

Specialty pharmacy and the hand-off nobody tracks

Approval is not the end. The prescription then moves to a specialty pharmacy, which may run its own benefits investigation, may need enrolment forms, and may require a nursing assessment before first dose. Each of those is another queue outside the practice’s systems.

The failure is rarely dramatic. A form goes out, nobody follows it, and the patient who was approved in week three starts therapy in week seven. Practices that track only to approval genuinely believe their turnaround is faster than the patient’s experience of it.

Track to first dose, not to approval. That single change in what you measure usually surfaces more delay than any other intervention, and it costs nothing but a column. Some of the follow-up it generates is well handled by a virtual check-in rather than a clinic slot the patient does not need.

Denial reason requirements and what changes in 2026

Federal rules are moving, and it is worth knowing precisely what they do and do not cover. the final rule itself applies to Medicare Advantage organizations, state Medicaid and CHIP fee-for-service programs, Medicaid and CHIP managed care entities, and qualified health plan issuers on the federally facilitated exchanges. Commercial employer coverage is not in scope, which matters a great deal if most of your biologics patients are commercially insured.

For the payers that are in scope, the CMS fact sheet sets the new timeframes: expedited decisions within 72 hours and standard decisions within seven calendar days, with exchange issuers excluded from the timeframe provisions. Impacted payers must also give a specific denial reason regardless of how the request was submitted, and must publicly report prior authorization metrics annually, with the first metrics due by 31 March 2026.

The denial reason requirement is the one to plan around. A specific reason is actionable in a way that a generic determination is not, and practices that capture the stated reason in a structured field will be able to see their own denial patterns for the first time.

Electronic prior authorization and the API rules

The same rule requires impacted payers to stand up a set of programming interfaces, including one for prior authorization, with those API requirements taking effect on 1 January 2027. Electronic prior authorization built on those interfaces is meant to let a practice discover what is required, submit, and receive a decision without leaving the chart.

Two caveats are worth holding onto. The obligation falls on payers, not on practices, so what arrives in your EHR depends on what your vendor builds against it. And the underlying standards work sits inside the national interoperability program, which means adoption will be uneven for a while even among payers who are in scope.

Plan for it, do not wait for it. A practice whose data is already structured will be ready to use an electronic pathway the week it appears. A practice whose justification still lives in prose will be retyping into a nicer interface. If the templates are being rebuilt anyway, it is worth rebuilding the workflow around it at the same time.

What the denial data actually shows

It is worth being precise about the scale of inappropriate denial, because the number gets repeated loosely. In a 2022 review, an OIG review of Medicare Advantage denials found that 13 percent of denied prior authorization requests met Medicare coverage rules, and 18 percent of denied payment requests met both coverage and billing rules. Two causes were identified: plans applying clinical criteria beyond Medicare’s own coverage rules, and requests denied for insufficient documentation where adequate records existed.

That second cause is the one a practice can act on directly. It is also the reason appealing is worth the effort more often than practices assume, and the reason a tracked, owned submission queue pays for itself.

Qventive provides biologics prior authorization rheumatology services across New Jersey as part of our rheumatology EHR and IT support and a broader rheumatology practice management engagement. Because authorization packets move detailed clinical information to third parties, the design belongs in your HIPAA risk analysis as well as your operations plan.

Biologics authorization: common questions